Matricelf Ltd Stock

MTLF

IL0011767915

Biotechnology & Medical Research

Market Closed - TEL AVIV STOCK EXCHANGE 23:24:21 10/11/2026 HKT			5-day change	1st Jan Change
244.00 ^ILa	+1.46%		+0.83%	-55.71%

09-03	Matricelf Receives FDA Feedback Supporting Key Elements Of Proposed First In Human Clinical Trial For NewRal Spinal Cord Injury Program	CI
08-27	Matricelf Ltd Reports Earnings Results for the Half Year Ended June 30, 2026	CI

Matricelf Ltd is an Israel-based company engaged in the biotechnology sector. The Company operates in the field of tissue engineering and regenerative medicine. The Firm develops a platform for autologous 3D printing of neutral human matrix, cells, tissues and organs implants. The implants are manufactured using cellular components originated from the patients themselves, to reduce potential immune response. The Company focuses on the treatment of spinal cord injury (SCI), but is also involved in developing treatment for additional medical conditions, including: Myocardial Infarction (MI), Parkinsonâ€™s disease and Age-related Macular Degeneration (AMD). Matricelf Ltd is a spin-out company from Tel Aviv University.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
10/11/26	ILA 244.00	+1.46%	5,502
09/11/26	ILA 240.50	-0.08%	22,795
06/11/26	ILA 240.70	-0.62%	2,812
05/11/26	ILA 242.20	-2.02%	32,878
04/11/26	ILA 247.20	+2.15%	58,557

Delayed Quote TEL AVIV STOCK EXCHANGE

More quotes

Stock Market
Stocks
MTLF Stock

Market Cap	80.75M 8.07B 25.36M 22.74M 20.96M 19.03M 36.02M 2.38B 37.03M 251M 99.98M 1.27B 95.16M 93.15M 4.03B	P/E 2024	-3.74x	P/E 2025	-3.65x
Enterprise Value	60.61M 6.06B 19.03M 17.07M 15.73M 14.29M 27.04M 1.78B 27.79M 188M 75.04M 956M 71.43M 69.91M 3.02B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	77.85%	Yield 2024 *	-	Yield 2025	-

09-03	Matricelf Receives FDA Feedback Supporting Key Elements Of Proposed First In Human Clinical Trial For NewRal Spinal Cord Injury Program	CI
08-27	Matricelf Ltd Reports Earnings Results for the Half Year Ended June 30, 2026	CI
07-09	Matricelf Ltd. Receives Approval to Begin Patient Identification and Blood Collection for Planned First-In-Human Spinal Cord Injury Study	CI
06-22	Matricelf Initiates Ind Enabling Efficacy Study for Engineered Human Neural Tissue Implant in Chronic Spinal Cord Injury	CI
06-17	Matricelf Completes GLP Safety Study for Engineered Neural Tissue Implant	CI
03-30	Matricelf Ltd. Enters into Collaborative Research Agreement with CiRA Foundation	CI
03-25	Matricelf Ltd Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-24	Matricelf and Sheba Medical Center Enter Strategic Collaboration to Advance First in Human Clinical Program in Spinal Cord Injury	CI
03-24	Matricelf Ltd Auditor Raises 'Going Concern' Doubt	CI
03-04	Matricelf Ltd. Reports Positive RNA Sequencing Results Demonstrating Promising Safety Profile Of Its Personalized Spinal Cord Implant	CI
03-03	Matricelf Ltd. Signs MOU to Establish Subsidiary for Commercialization of Parkinson's Disease Therapy	CI
03-03	Matricelf Ltd. (Tase Mtlf) signs MoU to establish subsidiary for commercialization of Parkinson's disease therapy	RE
02-27	Matricelf Ltd Appoints Ron Mayron as Active Chairman of the Board of Directors	CI

11-06	Matricelf Reports Statistically Significant Motor Function Improvement in Preclinical Efficacy Study of Chronic Spinal Cord Injury	NE
10-06	Matricelf to Meet Investment Banks at NIBA's 153rd Investment Conference Ahead of Planned Nasdaq Dual Listing and First in Human Studies	AQ
09-03	Matricelf Receives FDA Feedback Supporting Key Elements of Proposed First in Human Clinical Trial for NewRal Spinal Cord Injury Program	PR
07-09	Matricelf Continues Clinical Execution with Patient Enrollment Preparation Following GLP Safety Success and GMP Manufacturing Milestones	PR
06-23	Matricelf Initiates IND Enabling Efficacy Study Following Positive Preclinical Results in Spinal Cord Injury	AQ

1 day	+1.46%
1 week	+0.83%
Current month	-4.95%
1 month	-2.36%
3 months	-4.43%
6 months	-21.64%
Current year	-55.71%

1 week	235.8	249.9
1 month	230	270
Current year	212	853
1 year	212	853
3 years	204	853
5 years	204	1,275
10 years	204	1,555

Matricelf Ltd Stock

Stocks

MTLF

IL0011767915

Biotechnology & Medical Research

Valuation: Matricelf Ltd

Chart: Matricelf Ltd

Latest news: Matricelf Ltd

Press Releases: Matricelf Ltd

Quotes and Performance

Price Extremes

Managers and Directors: Matricelf Ltd

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Manager	Title	Age	Since
Asaf Toker CEO	Chief Executive Officer	54	01/06/2019
Tal Dvir CTO	Chief Tech/Sci/R&D Officer	52	01/06/2019
Alon Sinai COO	Chief Operating Officer	59	01/07/2019

Director	Title	Age	Since
Alon Sinai BRD	Director/Board Member	59	01/07/2019
Tal Dvir BRD	Director/Board Member	52	01/06/2019
Stanley Hirsch BRD	Director/Board Member	69	27/07/2022

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MATRICELF LTD	+1.46%	+0.83%	-43.45%	-36.06%	25.18M
WUXI APPTEC CO., LTD.	+0.01%	+11.10%	+60.83%	+70.43%	68.22B
ARGENX SE	+1.22%	+9.56%	+15.97%	+90.23%	59.82B
LONZA GROUP AG	+0.24%	+1.35%	+23.78%	+97.55%	56.07B
BEONE MEDICINES AG	+1.60%	+19.44%	+28.80%	+112.95%	47.67B
IQVIA HOLDINGS INC.	-1.32%	+4.78%	+29.15%	+40.40%	45.95B
REVOLUTION MEDICINES, INC.	-3.54%	-0.60%	+207.76%	+879.50%	43.29B
CELLTRION, INC.	-3.33%	+6.90%	+22.78%	+48.07%	35.66B
GENMAB A/S	-2.19%	-3.71%	+90.94%	+66.33%	34.73B
INSMED INCORPORATED	+2.92%	+14.41%	-37.74%	+403.12%	25.47B
Average	-0.29%	+4.80%	+39.88%	+177.25%	42B
Weighted average by Cap.	-0.41%	+5.50%	+50.74%	+180.54%

	2024	2025
Net sales	-	-
Net income	-15.58M -1.56B -4.89M -4.39M -4.04M -3.67M -6.95M -459M -7.15M -48.42M -19.29M -246M -18.36M -17.97M -777M	-27.82M -2.78B -8.74M -7.84M -7.22M -6.56M -12.41M -819M -12.76M -86.46M -34.45M -439M -32.79M -32.09M -1.39B
Net Debt	-10.68M -1.07B -3.35M -3.01M -2.77M -2.52M -4.76M -314M -4.9M -33.19M -13.22M -168M -12.59M -12.32M -533M	-20.14M -2.01B -6.32M -5.67M -5.23M -4.75M -8.98M -593M -9.24M -62.59M -24.94M -318M -23.74M -23.23M -1B